TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05927571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cevostamab
Description: Cevostamab solution for infusion will be administered as IV as specified in each treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cevostamab
Description: Cevostamab solution for infusion will be administered as IV as specified in each treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elranatamab
Description: Elranatamab solution for injection will be administered SC as specified in each treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elranatamab
Description: Elranatamab solution for injection will be administered SC as specified in each treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be used as rescue medication for participants who experience a cytokine release syndrome (CRS) event.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be used as rescue medication for participants who experience a cytokine release syndrome (CRS) event.
Study: NCT05331300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LASN01
Description: Escalating single and multiple doses of LASN01

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LASN01
Description: LASN01 will be administered intravenously
Study: NCT06183385

Intervention type: OTHER
Group type: OTHER
Intervention: Saliva collection
Description: Collection of 2 samples of 1.5 to 2mL of saliva by passive salivation in healthy volunteers

Intervention type: OTHER
Group type: OTHER
Intervention: Vaginal secretion collection
Description: Collection of vaginal secretions with 2 dry swabs in women

Intervention type: OTHER
Group type: OTHER
Intervention: IP-LC-MS/MS : immunoprecipitation enrichment with liquid chromatography coupled to tandem mass spectrometry
Description: sample preparation and analysis :~* Impregnation of the tips (absorbent cotton) of sterile dry swabs and vaginal swabs with controlled quantities of saliva.~* Immunocapture of salivary proteins of interest (histatin type 1, cystatin D, PRPs) by protein A affinity purification~* LC-MS/MS analysis of eluted purified peptides (Multiple Reaction Monitoring mode)~Dilutions will be made from 10 to 10 (1/10, 1/100, 1/1000...), then after reaching a detectability threshold, specified by a second more precise analysis (e.g. if no signal at 1/1000, analysis at 1/500 then 1/250 etc.). Analytical sensitivity will be tested on three samples of each type (salivary, vaginal, vaginal + semen) to ensure reproducibility of results.~Operators, unaware of the presence of saliva in the samples, will then carry out saliva-specific protein detection analysis using the IP-LC-MS/MS method.

Intervention type: OTHER
Group type: OTHER
Intervention: IP-LC-MS/MS : immunoprecipitation enrichment with liquid chromatography coupled to tandem mass spectrometry
Description: sample preparation and analysis :~* Impregnation of the tips (absorbent cotton) of sterile dry swabs and vaginal swabs with controlled quantities of saliva.~* Immunocapture of salivary proteins of interest (histatin type 1, cystatin D, PRPs) by protein A affinity purification~* LC-MS/MS analysis of eluted purified peptides (Multiple Reaction Monitoring mode)~Dilutions will be made from 10 to 10 (1/10, 1/100, 1/1000...), then after reaching a detectability threshold, specified by a second more precise analysis (e.g. if no signal at 1/1000, analysis at 1/500 then 1/250 etc.). Analytical sensitivity will be tested on three samples of each type (salivary, vaginal, vaginal + semen) to ensure reproducibility of results.~Operators, unaware of the presence of saliva in the samples, will then carry out saliva-specific protein detection analysis using the IP-LC-MS/MS method.
Study: NCT05331300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LASN01
Description: LASN01 will be administered intravenously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Escalating doses of matching placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered intravenously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered intravenously
Study: NCT05960604

Intervention type: DIAGNOSTIC_TEST
Intervention: Passive leg raising
Description: All patients who met the inclusion criteria will be placed head down flat and feet up at a 45° angle for 30 seconds.~Hemodynamic parameters and analysis by pressure recording analytical method obtained with the MostCare will be collected before, during and after the test until the end of the surgery.~The total duration of the intervention (passive leg raising) is 30 seconds. The total duration of hemodynamic parameters recording is expected to be 60-600 minutes.

Intervention type: DIAGNOSTIC_TEST
Intervention: Passive leg raising
Description: All patients who met the inclusion criteria will be placed head down flat and feet up at a 45° angle for 30 seconds.~Hemodynamic parameters and analysis by pressure recording analytical method obtained with the MostCare will be collected before, during and after the test until the end of the surgery.~The total duration of the intervention (passive leg raising) is 30 seconds. The total duration of hemodynamic parameters recording is expected to be 60-600 minutes.
Study: NCT06534255

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MegaLT injection
Description: Three dose groups were set: 1×10\^6/kg, 5×10\^6/kg, and 1×10\^7/kg. The dose escalation was carried out in ascending order using a 3+3 design. To ensure participant safety, enrollment followed a 1+2 rule. Specifically, the first participant in each dose group received the cell infusion and was observed for 14 days. If no dose-limiting toxicity (DLT) was observed, the remaining two participants could then be enrolled and receive cell therapy at the same dose level.
Study: NCT05804565

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Saw
Description: The surgeon will use an oscillating microsaw to transect the metatarsal shaft

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bone Cutter
Description: The surgeon will use a manual bone cutter to transect the metatarsal shaft
Study: NCT05713617

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PODER Familiar
Description: Educational intervention designed to improve healthy behaviors of families of children with intellectual and developmental disabilities.
Study: NCT05726929

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic treatment
Description: Osteopathic Manual Treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Capsaicin QUTENZA Patch (TAU)
Description: Capsaicin QUTENZA Patch is the treatment as usual (TAU) delivered in the medical algology service

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin QUTENZA Patch (TAU)
Description: Capsaicin QUTENZA Patch is the treatment as usual (TAU) delivered in the medical algology service
Study: NCT05835895

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GNSC-001
Description: intra-articular injection

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GNSC-001
Description: intra-articular injection

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GNSC-001
Description: intra-articular injection

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GNSC-001
Description: intra-articular injection

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GNSC-001
Description: intra-articular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: transient immune-modulation
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: transient immune-modulation
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: transient immune-modulation
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: transient immune-modulation
Description: intra-articular injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intra-articular injection
Study: NCT05012696

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV)
Description: Non-invasive ventilation will be provided through a mechanical ventilator (Carina, Dräger) through a facial interface (Fitlife Respironics, Philips). A PEEP level between 5 and 10 cmH2O, minimal pressure-support level of 5 cm H2O targeting a tidal volume around 6 to 8 ml/kg and at the same FiO2 applied during the spontaneous breathing trial.
Study: NCT05517148

Intervention type: DEVICE
Group type: OTHER
Intervention: Therapeutic VR
Description: Treatment module categories included: (1) Mindfulness-based stress reduction training: an audio conducting practice with breathing-based biofeedback training in immersive and interactive environments to support self-regulation and relaxation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic VR
Description: Treatment module categories included: (1) Mindfulness-based stress reduction training: an audio conducting practice with breathing-based biofeedback training in immersive and interactive environments to support self-regulation and relaxation.
Study: NCT05143346

Intervention type: DEVICE
Group type: OTHER
Intervention: Intubation
Description: Using video stylet and video laryngoscope in difficult intubation in patients with trauma or suspected to be have difficult intubation.

Intervention type: DEVICE
Group type: OTHER
Intervention: Intubation
Description: Using video stylet and video laryngoscope in difficult intubation in patients with trauma or suspected to be have difficult intubation.
Study: NCT05446857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir / Pibrentasvir Pill
Description: Glecaprevir 100 mg/Pibrentasvir 40 mg, 3 oral tablets once daily for 8 weeks.
Study: NCT05138588

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS
Description: For each subject, a verum condition and a control condition will be programmed. We will use the QPS-5 method (4 pulses, Inter-Stimulation Interval; ISI: 5 seconds).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: For each subject, a verum condition and a control condition will be programmed. We will use the QPS-5 method (4 pulses, Inter-Stimulation Interval; ISI: 5 seconds).
Study: NCT05511610

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sevoflurane uptake and supply
Description: Phase sevo 1)~* Moment 1 (M1): from OTI until end-tidal sevoflurane (etSEVO%) exceeds ettSEVO% by 10%. Deliver of sevoflurane to the system (SEVOdel) carried out by completely opening sevoflurane vaporizer (8%).~* M2) once etSEVO% surpass ettSEVO% by 10%: turn off sevoflurane vaporizer and observe the progressive fall etSEVO%. When etSEVO% approaches ettSEVO% (0.1-0.2 points above ettSEVO%), the investigators will turn on the sevoflurane vaporizer following the MAAS method to ensure stability in inspired and expired concentrations of sevoflurane.~Phase sevo 2) Objective: to maintain etSEVO% = ettSEVO% ±5% When the etSEVO% increases above the mentioned levels \>\> reduce SEVOdel by 0.25-0.5%.~When the etSEVO% decreases below the mentioned levels\>\> increase SEVOdel by 0.25-0.5%.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Washout phase
Description: The investigators will close the sevoflurane vaporizer and will start the administration of Propofol in intravenous perfusion; the investigators will then open the FGF sequentially at 2\>5\>10 liters per minute (LPM), until the etSEVO% is \<0.2 MAC.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Desflurane uptake and supply
Description: Phase desflu 1)~* Moment 1 (M1): from the end of Washout phase until end-tidal desflurane (etDESFLU%) exceeds ettDESFLU% by 10%. Deliver of desflurane to the system (DESFLUdel) carried out by completely opening the desflurane vaporizer (18%).~* M2) once etDESFLU% surpass ettDESFLU% by 20%: turn off the desflurane vaporizer and observe the progressive fall etDESFLU%. When etDESFLU% approaches ettDESFLU% (0.8-1.2 points above ettDESFLU%), the investigators will turn on the desflurane vaporizer following the MAAS method to ensure stability in inspired and expired concentrations of desflurane.~Phase desflu 2) Objective: to maintain etDESFLU% = ettDESFLU% ±5% When the etDESFLU% increases above the mentioned levels \>\> reduce DESFLUdel by 0.25-0.5%.~When the etDESFLU% decreases below the mentioned levels\>\> increase DESFLUdel by 0.25-0.5%.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Final phase
Description: From the end of Phase desflu 2 until the end of the intervention. Maintenance of anesthesia with desflurane following the principles of MAAS Method.~Between 15-20 minutes before the end of the intervention, the investigators will stop the administration of desflurane, registering the time until the reaching etDESFLU% \< 0.2 MAC.
Study: NCT01535521

Intervention type: DEVICE
Group type: OTHER
Intervention: Sleep Position Trainer (SPT)
Study: NCT06343467

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Generic Volar Locking Plate
Description: Application of a generic volar locking plate is done in the generic implant arm compared to the other commonly used implants by surgeons in the conventional implant arm.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Volar Locking Plate
Description: Application of a conventional, brand name volar locking plate is done in the conventional implant arm compared to the generic implant arm.
Study: NCT04594772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folfirinox
Description: Chemotherapy will begin with FOLFIRINOX - a standard regimen used in pancreatic cancer treatment, consisting of 5-fluorouracil (2400 mg/m2), irinotecan (180 mg/m2) and oxaliplatin (85 mg/m2). Treatment will continue for 2 cycles (4 doses), and then re-evaluation will be performed. If a decision to continue with FOLFIRINOX is made, it will be administered for another 4 cycles (8 doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: At the first planned analysis, if a switch is indicated based on prespecified criteria , gemcitabine (1000 mg/m2) and nab-paclitaxel (125 mg/m2) - another standard regimen in this setting - will be used. It will be administered for 4 cycles (12 doses).
Study: NCT05012696

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV)
Description: Non-invasive ventilation will be provided through a mechanical ventilator (Carina, Dräger) through a facial interface (Fitlife Respironics, Philips). A PEEP level between 5 and 10 cmH2O, minimal pressure-support level of 5 cm H2O targeting a tidal volume around 6 to 8 ml/kg and at the same FiO2 applied during the spontaneous breathing trial.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula
Description: High flow nasal cannula will be provided through a commercial device (AIRVO2 + Optiflow nasal cannula, Fisher \& Paykel), at 50 LPM and at the same FiO2 applied during the spontaneous breathing trial.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula
Description: High flow nasal cannula will be provided through a commercial device (AIRVO2 + Optiflow nasal cannula, Fisher \& Paykel), at 50 LPM and at the same FiO2 applied during the spontaneous breathing trial.
Study: NCT03734731

Intervention type: DEVICE
Group type: OTHER
Intervention: Monochromatic Infrared Photo Energy (MIRE)
Description: Apply Monochromatic Infrared Photo Energy (MIRE) to the affected nerve

Intervention type: DEVICE
Group type: OTHER
Intervention: Transcutaneous Electrical Nerve Stimulation
Description: Apply Transcutaneous Electrical Nerve Stimulation (TENS) to the affected nerve

Intervention type: DRUG
Group type: OTHER
Intervention: Opioids
Description: Prescribe Opioids to treat for pain or circulatory disorders, dosage to be determined by Principal Investigator

Intervention type: DRUG
Group type: OTHER
Intervention: Cannabis
Description: Prescribe Cannabis to treat for pain or circulatory disorders, dosage to be determined by Principal Investigator. Comparing Opioid results to Cannabis results with objective nerve testing
Study: NCT04594772

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Radiation therapy may be used prior to surgery, based on findings on the final pre-operative scan per standard of care. Radiation therapy will be delivered in patients with artery and venous involvement meeting the Intergroup definition for borderline resectable disease. Radiotherapy will be delivered via a hypofractionated approach over 10 fractions and will include target volumes to the primary tumor and elective coverage of vascular structures at risk. Radiation will be delivered with concurrent chemotherapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pancreatectomy
Description: Pancreatectomy should occur within 4 to 8 weeks after the last dose of preoperative chemotherapy. Staging laparoscopy may be performed at the time of planned laparotomy but is not required. Either standard or pylorus-preserving pancreaticoduodenectomy, distal subtotal pancreatectomy, or total pancreatectomy may be performed. Surgical drains and enteral tubes (e.g. gastrostomy and/or jejunostomy tubes) may be placed at the discretion of the operating surgeon.
Study: NCT04547985

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone HCl 50 MG Oral Tablet
Description: Generic, oral tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Composed of filler material and encapsulated to appear identical to naltrexone.
Study: NCT04831411

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Arthroplasty
Description: The extremities of patients admitted to the operating room to be applied TKA will be determined using a safe surgical Fast-Track recovery protocol. Patients will be operated by the same surgical team using the same technique. Spinal anaesthesia or general anaesthesia will be applied to the patients according to the evaluations of the anesthesiologists.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Arthroplasty
Description: The extremities of patients admitted to the operating room to be applied TKA will be determined using a safe surgical Fast-Track recovery protocol. Patients will be operated by the same surgical team using the same technique. Spinal anaesthesia or general anaesthesia will be applied to the patients according to the evaluations of the anesthesiologists.
Study: NCT04136951

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PREVENT clinical decision support
Description: PREVENT clinical decision support tool consideres five patient risk factors as significant predictors of patient's priority for the first homecare nursing visit: (a) Presence of wounds (either surgical or pressure ulcers); (b) a documented comorbid condition of depression; (c) need for assistive equipment, assistive person, or both for toileting; (d) number of medications; and (e) number of comorbid conditions. Each risk factor was assigned a specific score based on the logistic regression weights. For instance, for a wound (e.g., pressure ulcer, vascular ulcer), the patient received a score of 15 points. For each additional co-morbid condition, one point was added to the final score. Summing the scores for the factors generated a cumulative score. The optimal cut-off point was established based on the regression model performance statistics, indicating that patients with a score greater than 26 points are a high priority for the first nursing visit.
Study: NCT05590819

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation(rTMS)
Description: 5 hertz(Hz), 1000 pulses, 90% RMT stimulation; 15 minutes per session; for a total of 10 sessions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation(rTMS)
Description: 5 hertz(Hz), 1000 pulses, 90% RMT stimulation; 15 minutes per session; for a total of 10 sessions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Theta-burst Stimulation(iTBS)
Description: 3 pulses of stimulation delivered at 50 Hz and repeated at 5 Hz; 2s train of TBS with repetitive interval of every 10s, 70% RMT; 600 pulses in total; 15 minutes per session; for a total of 10 sessions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Theta-burst Stimulation(iTBS)
Description: 3 pulses of stimulation delivered at 50 Hz and repeated at 5 Hz; 2s train of TBS with repetitive interval of every 10s, 70% RMT; 600 pulses in total; 15 minutes per session; for a total of 10 sessions

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham stimulation
Description: Set-up the coil without true stimulation; 15 minutes per session; for a total of 10 sessions

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham stimulation
Description: Set-up the coil without true stimulation; 15 minutes per session; for a total of 10 sessions
Study: NCT05812651

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle fatigue
Description: Muscle training according to the protocol that tends to induce inspiratory muscle fatigue. (60-80% MIP). Inspiratory resistive loading by starting at 60-80% (MIP) increasing every 10 minutes by 10% then measure MIP, until MIP measurement decrease of more than 10% from baseline will be performed.~When report a lower score of MIP and participants could no longer worked out, performed the functional mobility tests and see if there any variation.
Study: NCT05594979

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TOTUM-070
Description: 2.5-g dose of TOTUM-070 diet supplement; Four capsules per day to consume orally in two intakes
Study: NCT04831411

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole Body Vibration
Description: Whole Body Vibration

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Resistance Training
Description: Progressive Resistance Training
Study: NCT06456346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bomedemstat
Description: Oral capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyurea
Description: Oral capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bomedemstat placebo
Description: Oral capsule placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea placebo
Description: Oral capsule placebo
Study: NCT05888597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-menthol
Description: (Sigma-Aldrich, St. Louis, US)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Strawberry scent (Sigma-Aldrich, St. Louis, US)